Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company dedicated to the research and development of novel antibody-based drugs through innovative technologies. Headquartered in Beijing, China, the company's mission is to become a global leader in new drug discovery, aiming to deliver therapeutic benefits to patients worldwide. Beyond its main base, Biocytogen maintains a significant international presence with branches in Haimen (Jiangsu), Shanghai, the United States (Boston, San Francisco, San Diego), and Germany (Heidelberg).

The company's core business encompasses a range of preclinical research services, including gene-editing, preclinical pharmacology and efficacy evaluation, and the sale of animal models under its BioMice™ sub-brand, which features genetically engineered and disease-specific mouse models. Biocytogen leverages proprietary platforms such as RenMice® (comprising RenMab™, RenLite®, RenNano®, and RenTCR-mimic™) for the discovery of fully human monoclonal, bispecific, multispecific, and nanobody antibodies. These platforms support a vast library of over one million fully human antibody sequences, enabling the development of innovative drug candidates primarily in oncology, autoimmune, metabolic, and neurological disorders.

Under the leadership of Chairman, CEO, and General Manager Dr. Yuelei Shen, Biocytogen is publicly traded on both the Hong Kong Stock Exchange (HKEX: 02315) and the Shanghai Stock Exchange STAR Market (SSE: 688796), making it the first "H+A" dual-listed global drug innovator. The company is actively pursuing "Project Integrum," a large-scale initiative to discover first-in-class and best-in-class antibody drugs targeting over 1,000 potential therapeutic targets. Recent notable developments include a strategic partnership with Sihuan Pharmaceutical in April 2026 to advance therapies, including for weight loss, and a licensing agreement with BeOne Medicines in July 2025 for multiple fully human antibodies. Biocytogen also announced the FDA IND clearance for partner NEOK Bio's NEOK002 and the dosing of the first patient in a Phase 1 trial for IDEAYA's IDE034 in early 2026.